LGALS17A: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: LGALS17A

NCBI ID: G400696

LGALS17A

Other Name(s): galectin 14 pseudogene | Galectin 14 pseudogene

LGALS17A: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States, over 21,000 women will be diagnosed with the disease in 2020. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer remains relatively stagnant , with a five-year survival rate of only 25%. The lack of effective treatment options for this disease has led to a growing interest in the potential of new biomarkers and drug targets.

One potential drug target for ovarian cancer is LGALS17A, a gene that has been identified as a pseudogene for the protein galectin-14 (LGALS14). Galectin-14 is a transmembrane glycoprotein that is expressed in various tissues and has been shown to play a role in cancer progression. In particular, it has been shown to be overexpressed in many types of cancer, including ovarian cancer.

While further research is needed to fully understand the role of LGALS17A in ovarian cancer, studies have shown that it is a potential drug target. For example, researchers have found that LGALS17A is highly expressed in ovarian cancer tissues and that inhibiting its activity may be an effective way to treat the disease. Additionally, there are several drugs that have been shown to target LGALS17A, including inhibitors of the tyrosine kinase receptor (TKR) and the protein kinase A (PPK), as well as small molecules that can inhibit the activity of LGALS17A.

In addition to its potential as a drug target, LGALS17A is also a potential biomarker for ovarian cancer. This is because it is often overexpressed in ovarian cancer tissues and can be used as a marker for the disease. For example, researchers have found that LGALS17A levels are often elevated in ovarian cancer tissues and that they can be used to predict the outcomes of ovarian cancer patients. Additionally, because LGALS17A is also expressed in other tissues, it may be a useful biomarker for other types of cancer as well.

While further research is needed to fully understand the role of LGALS17A in ovarian cancer, it is clear that it is an important molecule that should be further studied. The potential of LGALS17A as a drug target and biomarker for ovarian cancer makes it an attractive target for researchers to investigate further. By developing new treatments that target LGALS17A, researchers may be able to improve the treatment options for ovarian cancer and reduce the number of women who are diagnosed with this devastating disease.

Protein Name: Galectin 14 Pseudogene

The "LGALS17A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LGALS17A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets